BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
about
ABL tyrosine kinases: evolution of function, regulation, and specificityThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisCrystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activityThe SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motionA novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Abl kinase constructs expressed in bacteria: facilitation of structural and functional studies including segmental labeling by expressed protein ligationABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.Using functional genomics to overcome therapeutic resistance in hematological malignancies.Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.Modular evolution of phosphorylation-based signalling systems.Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisContribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceABL1 fusion genes in hematological malignancies: a review.Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Ever-advancing chronic myeloid leukemia treatment.Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.Atomic view of the energy landscape in the allosteric regulation of Abl kinase.Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion.Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.
P2860
Q24299738-AF32C518-09CD-4605-A4F4-173E1EB3295CQ26866312-A5DF2CC7-E225-4663-8430-6B7CF6F0F076Q27028181-D5B7827A-E891-41D5-9AA6-100C27ACA1F9Q27667482-169B5103-7A98-482A-9AE4-3E1F9DAAEB5CQ27675049-C18A1F17-D3D5-4E3E-99F6-F6CAB22ACFADQ27698513-3BBA0135-3F02-4660-963A-2DCD133A9180Q28543640-60FBFC4B-EFBE-4D38-8C06-B916415746E0Q30008897-AD4D4224-36FE-4A70-AA13-923A91FE8EA2Q30009238-82CBFCF3-0DE7-4913-BD1D-1379A9267470Q30009530-752E0D45-A192-437A-895A-4FE51CC25D44Q30010105-B522F334-C90E-42A4-844B-094CBD377478Q30155948-757D9560-A69C-4A01-84E2-23AFA9E2EA82Q34401328-37B5A1F4-CA45-445C-B2D4-9F4CCA0FFC66Q35104426-FC577E5B-A6BD-4D94-BDD2-23D5BCBCCA5EQ35812209-ECF7D73A-A011-4DE5-90F3-8B83CD8DDE5FQ36153880-4021E352-DA61-4A0D-BCDB-377D4EAB4AEBQ36437173-9B58972E-DC64-4C54-A529-25FBF47339A6Q36562926-3A2F079F-8611-4AF6-84E0-1A1BCE161CB8Q36884733-07E83AF2-B27E-49AD-B384-AA9FEED9545DQ37857340-C43D012F-F383-4ADE-8974-28502F6E4A38Q37911537-7D13FD0A-07B2-48E5-8D22-CA8E2379EFCFQ38044753-53420512-B6C5-4BCD-AB1F-BE2E7055AFA2Q38164565-64124725-8B00-49D1-9A04-45917E1A7CA9Q38562354-114773B6-C690-477A-BDDF-81DA32598AC5Q39277365-ED9AA6D5-5B16-4D84-BDB2-85EF7752B8F2Q40336921-DDCDDCB7-67C0-470A-AA1D-0CDE4A43E69EQ42380473-B1F44A18-3168-400C-9E04-DC350C8C9620Q47748395-EC5076BA-92A2-4847-89FC-51C2C7090C73Q50053531-247F235E-74F7-4E1C-AC15-93E263A7E3C1Q52655033-5CA593FE-9500-45B4-8582-A6AA03AAEBC2Q54558408-D3B01468-BF80-43E9-8ADB-9ADACAA2DA67Q54600753-E44C0E65-DCD7-4298-9BE7-BA33CE4E10F3
P2860
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@ast
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@en
type
label
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@ast
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@en
prefLabel
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@ast
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@en
P2093
P2860
P921
P1433
P1476
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
@en
P2093
Daniel W Sherbenou
Kim-Hien Dao
Lalita P Turaga
Michael W Deininger
Stephanie Willis
Thomas Bumm
Thoralf Lange
P2860
P304
P356
10.1182/BLOOD-2008-10-183665
P407
P577
2010-06-02T00:00:00Z